Company

Company Story

Manchester BIOGEL (MBG), is a leader in the design and manufacture of peptide hydrogels that are redefining cell culture for life sciences. See below for key milestones in our development to date, and also hear directly from our Founders how and why the company started.

Timeline

2020
”September

Company secures investment from Deepbridge Capital Ltd and Catapult Ventures Greater Manchester and Cheshire Fund
”August

Launch of Innovate funded KTP project in partnership with Imperial College London
”August

Company operating at ISO13485
”June

11 PhD CASE studentships and one PDRA started across the UK & Ireland
”March

Manchester BIOGEL doubles office and lab footprint at Alderley Park
2019
”April

Launch functionalised PeptiGels® & PeptiInks®
”April

4 more people added to the, now, 8-person team
2018
”August

Company re-launched as Manchester BIOGEL Ltd
”August

2 more people added to the, now, 4-person team
2017
”August

Company secures investment from KERO Ltd
”February

Materials platform technology extended to include functional materials
2016
”August

PeptiGel® Alpha series launched
”August

Opened lab & office at Alderely Park, Cheshire, UK
2015
”August

First PeptiGel® launched
”August

Company grows to two employees
”August

Company receives investment from Deepbridge Capital
2014
”September

IP & know-how licensed from The University of Manchester
”August

Company was founded as PeptiGelDesign Ltd
2002
”August

A seed grant was awarded from The University of Manchester to begin the research

Interviews with our founders

With a combined 40 years of research experience and more than 100 publications between them, Professors Aline Miller and Alberto Saiani have an extensive knowledge of how to design and create a biomaterial that meets the needs of scientists in the life science and healthcare sectors.

Watch these short videos to find out how their work led them to develop our synthetic hydrogel technology, PeptiGels® and PeptiInks® for tissue engineering, regenerative medicine and drug discovery applications.

Aline Miller, BSc(Hons) PhD FRSC FInstP

Chief Executive Officer, Director and Founder

Alberto Saiani, PhD FInstP MRSC

Chief Scientific Officer and Founder

Get in touch

For more information about our technology, our products or how we can support your research please get in touch: